Taiwan-based Repurgenesis said in late July 2026 that it had signed a memorandum of understanding with Switzerland-based Medvisis to pursue AI-assisted drug repurposing. The public announcement names a platform and a commercial network, but not a candidate, dataset, validation plan or binding development milestone.
OpenAI and Molecule.one reported on June 17 that a GPT-5.4 workflow helped identify conditions that improved a difficult Chan-Lam coupling across 10,080 microscale reactions. An automated laboratory supplied the testing capacity, while chemists selected proposals, corrected plans and repeated key experiments by hand.
OpenAI reported in June 2026 that GPT-Rosalind passed 36.1 percent of the 750 tasks in its new LifeSciBench evaluation. Performance fell on tasks involving figures, files or web sources, while the benchmark's design and publication by OpenAI complicate interpretation of its model rankings.
